Theravance Appoints CBO

Michael E. Faerm has been appointed senior vice president and chief business officer at Theravance, Inc. Mr. Faerm reports to Michael W. Aguiar, chief executive officer, and will lead Theravance’s growth strategy and corporate development initiatives beyond the company’s existing respiratory portfolio of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.

Mr. Faerm has 17 years of pharmaceutical and biotechnology experience, spanning equity research, biopharmaceutical industry and investment banking roles. Most recently, he served as senior Pharmaceuticals Equity Research Analyst at Wells Fargo Securities. Prior to Wells Fargo, he spent seven years in equity research at Credit Suisse, where he was most recently the firm’s senior Specialty Pharmaceuticals Analyst, and spent four years in investment banking as a member of Merrill Lynch’s global healthcare team, where he focused primarily on mergers and acquisitions and financings of biotechnology and pharmaceuticals companies.

“Michael brings a unique perspective with his depth and breadth of experience in the biopharmaceutical industry, equity research and investment banking. His experience and relationships will strengthen the Theravance team as we continue to work closely with GlaxoSmithKline to maximize the value of our product portfolio,” said Michael W. Aguiar, president and chief executive officer of Theravance.